Intubation or death up to 30 days after diagnosis of COVID-19 served as the primary endpoint in a population-based study analyzing obesity as an independent risk factor for COVID-19.
Meeting public demand for an urgently needed effective medication quickly and safely during a pandemic involves difficult tradeoffs.
A widely cited model for COVID-19 deaths in the United States predicts a total of 317,000 deaths by December.
Results from a retrospective study found that obesity in men and younger patients with COVID-19 was associated with an increased risk for death.
Acute pancreatitis may be a gastrointestinal manifestation of COVID-19.
Children who received a new diagnosis of type 1 diabetes during the COVID-19 pandemic are presenting with higher rates of diabetic ketoacidosis than in the previous 2 years.
This study found that diabetic patients with COVID-19 had lower lymphocyte counts and hospital stays.
The treatment of patients with familial hypercholesterolemia and COVID-19 with dyslipidemia medications may prevent the occurrence of thrombotic events.
Several questions remain regarding the effect of COVID-19 infection and hypercoagulation in the management of patients taking oral contraceptives, estrogen therapy, and patients who are pregnant.
For COVID-19 patients without a previous diagnosis of diabetes, fasting blood glucose ≥7.0 mmol/L is an independent predictor of 28-day mortality.
